Analisi Organizzativa e di Budget Dell'introduzione di Vedolizumab Vs Terapie Tradizionali in Colite Ulcerosa e Morbo di Crohn: Implicazioni Economiche Nel Confronto Con Adalimumab, Infliximab e Golimumab

Global & Regional Health Technology Assessment

MatteoRuggeri¹ 

关键词: Activity-based costing;    Anti-TNF treatments;    Crohn's disease;    Inflammatory bowel disease;    Ulcerative colitis;    Vedolizumab;   

DOI  :  10.5301/grhta.5000258

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

Activity-based costing and budget analysis of vedolizumab versus conventional treatments in ulcerative colitis and Crohn's diseaseObjectiveTo assess the organizational impact of the introduction of vedolizumab compared to the biotechnological anti-TNF alternatives to date available in Italy for the management of Ulcerative Colitis (UC) and Crohn's Disease (CD).MethodsA questionnaire aimed at acquiring data about the Italian real practice concerning the management of patients affected by UC and CD was administered to a panel of expert clinicians from three Italian centers of excellence. The determination of the cost of the therapies was realized through an Activity-Based Costing (ABC) analysis which identified the differential between the use of vedolizumab and the alternatives.ResultsThe reduced time of infusion of vedolizumab allows a total cost/infusion of €97.89, with savings vs. infliximab of €39.60 (UC and CD). Vedolizumab implies an expenditure of €17,229.84 (UC) and €17,459.63 (CD) in the first yea...

【 授权许可】

CC BY